ArticleGastroenterology research and practice2025
Effects of Ozone Therapy on Adverse Events and Inflammatory Markers in Patients With Hepatocellular Carcinoma Undergoing Interventional Therapy.
Article in Gastroenterology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There has been very limited investigation regarding reduced interventional therapy-related adverse events in patients with hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of ozone therapy as an adjunctive treatment on inflammation markers and adverse events in patients with HCC receiving interventional therapy. Methods: Three hundred and forty-two patients with HCC undergoing interventional therapy were enrolled from December 2020 to June 2023, of which 221 patients received rectal ozone insufflation therapy (ozone cohort), and the other 121 patients did not receive ozone therapy (control cohort). The information on treatment-related adverse events (TRAEs) was retrieved and analyzed. Results: In the study, most clinical characteristics between the ozone and control cohorts showed no significant differences. In the ozone cohort, 122 patients (55.2%) reported TRAEs of any grade, compared with 67 (55.4%) patients in the control cohort ( Conclusion: Ozone therapy did not significantly decrease the incidence of adverse events or mitigate the increase in inflammatory markers. Further research with a larger sample size is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.